中邮证券研报指出,恒瑞医药前三季度实现归母净利润57.5亿元(+24.5%),25Q3收入归母净利润13.0亿元(+9.5%)。25Q3收入增速符合预期,预计确认的BD首付款占比不大,内生增速相对稳健,预计创新药销售收入仍保持较快增长。综合公司Q3现金流量表以及资产负债表中合同负债项目(25Q3为39.71亿元、25H1为1.61亿元),预计授予GSKPDE3/4抑制剂HRS-9821等多项药物...
Source Link中邮证券研报指出,恒瑞医药前三季度实现归母净利润57.5亿元(+24.5%),25Q3收入归母净利润13.0亿元(+9.5%)。25Q3收入增速符合预期,预计确认的BD首付款占比不大,内生增速相对稳健,预计创新药销售收入仍保持较快增长。综合公司Q3现金流量表以及资产负债表中合同负债项目(25Q3为39.71亿元、25H1为1.61亿元),预计授予GSKPDE3/4抑制剂HRS-9821等多项药物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.